Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 20/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 20/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 19/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28652777 | 0.83 | CHRM1 (0.54) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL16292414 | 0.78 | CHRM5 (0.54) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL16292313 | 0.78 | CHRM1 (0.53) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL17259804 | 0.77 | CHRM1 (0.44) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL17259986 | 0.77 | CHRM1 (0.44) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL17259989 | 0.77 | CHRM1 (0.44) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL17259802 | 0.77 | CHRM1 (0.44) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL16292719 | 0.76 | CHRM1 (0.50) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL16292844 | 0.76 | CHRM1 (0.48) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL16293284 | 0.76 | CHRM5 (0.55) | CHRM1CHRM3CHRM5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673906-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | disclosed |
| US-9126993-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM1 4878/4885CHRM3 4870/4885CHRM5 4875/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM1 4879/4885CHRM3 4870/4885CHRM5 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.